Data were analyzed from 2023 to 2025.<h4>Intervention</h4>Single intravenous infusion of IL-6R antagonist tocilizumab (8 mg/kg, maximum 800 mg/patient) or normal saline.<h4>Main outcomes and measures</h4>The primary outcome was depression somatic symptoms at 14 days after infusion. Here, IL6R is linked to major depressive disorder.